Clinical trial
A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A
Name
EFC16295
Description
Primary Objective:
- To evaluate the safety of BIVV001 in previously treated pediatric participants with hemophilia A.
Secondary Objectives:
* To evaluate the efficacy of BIVV001 as a prophylaxis treatment.
* To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes.
* To evaluate BIVV001 consumption for prevention and treatment of bleeding episodes.
* To evaluate the effect of BIVV001 prophylaxis on joint health outcomes.
* To evaluate the effect of BIVV001 prophylaxis on Quality of Life (QoL) outcomes.
* To evaluate the efficacy of BIVV001 for perioperative management.
* To evaluate the safety and tolerability of BIVV001 treatment.
* To assess the pharmacokinetics (PK) of BIVV001.
Trial arms
Trial start
2021-02-19
Estimated PCD
2023-01-18
Trial end
2023-01-18
Status
Completed
Phase
Early phase I
Treatment
efanesoctocog alfa (BIVV001)
Pharmaceutical form: solution for injection Route of administration: IV
Arms:
BIVV001: Participants aged 6 to <12 Years, BIVV001: Participants aged <6 Years
Size
74
Primary endpoint
Number of Participants With Neutralising Antibodies (Development of Inhibitors) Directed Against Factor VIII
Baseline up to Week 52
Eligibility criteria
Inclusion criteria :
* Participant must be younger than 12 years of age, at the time of signing the informed consent.
* Severe hemophilia A defined as \<1 international units per deciliter (IU/dL) (\<1 percent \[%\]) endogenous Factor VIII (FVIII) as documented either by central laboratory testing at Screening or in historical medical records from a clinical laboratory demonstrating \<1% FVIII coagulant activity (FVIII:C) or a documented genotype known to produce severe hemophilia A.
* Previous treatment for hemophilia A (prophylaxis or on-demand) with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 exposure days (EDs) for participants aged 6 to \<12 years and above 50 EDs for participants aged \<6 years.
* Weight above or equal to 10 kg.
Exclusion criteria:
* History of hypersensitivity or anaphylaxis associated with any FVIII product.
* History of a positive inhibitor (to FVIII) test defined as greater than or equal to (\>=) 0.6 Bethesda units (BU/mL), or any value greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs for inhibitor detection between 0.7 and 1.0 BU/mL, or clinical signs or symptoms of decreased response to FVIII administrations. Family history of inhibitors would not exclude the participant.
* Positive inhibitor test result, defined as \>=0.6 BU/mL at Screening.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 74, 'type': 'ACTUAL'}}
Updated at
2024-02-13
1 organization
1 product
1 indication
Product
Efanesoctocog alfaIndication
Hemophilia AOrganization
Bioverativ